2008
Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial.
Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, Mohamed S, Jeste DV. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. The Journal Of Clinical Psychiatry 2008, 70: 562-71. PMID: 19192468, DOI: 10.4088/jcp.08m04261.Peer-Reviewed Original ResearchConceptsQuality of lifeSubsyndromal symptomsSchizoaffective disorderOlder patientsOlder outpatientsTreatment groupsRandomized placebo-controlled trialRating ScaleFlexible-dose treatmentSecondary efficacy analysesPlacebo-controlled trialCurrent antipsychotic medicationsDepression Rating ScaleGeneral medical healthHamilton Rating ScaleCalgary Depression Rating ScaleYears of ageDSM-IV schizophreniaCitalopram augmentationAdverse eventsPlacebo augmentationEfficacy analysisAntipsychotic medicationStudy criteriaDimensions of schizophrenia
2007
Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia
Zisook S, Montross L, Kasckow J, Mohamed S, Palmer BW, Patterson TL, Golshan S, Fellows I, Lehman D, Solorzano E. Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia. American Journal Of Geriatric Psychiatry 2007, 15: 1005-1014. PMID: 18056819, DOI: 10.1097/jgp.0b013e3180a725ec.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsChronic DiseaseCitalopramComorbidityDepressionDepressive Disorder, MajorDouble-Blind MethodFemaleFollow-Up StudiesHealth StatusHumansMaleMiddle AgedPlacebosPsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologySelective Serotonin Reuptake InhibitorsSuicideTreatment OutcomeConceptsSubsyndromal depressive symptomsDepressive symptomsOlder patientsClinical featuresSchizoaffective disorderNegative symptomsHamilton Depression Rating ScaleImportant clinical dimensionGeneral medical conditionsDepression Rating ScaleSpecific depressive symptomsMental functioningSubstantial morbiditySevere akathisiaMovement abnormalitiesChronic schizophreniaMedical conditionsDepression groupOverall psychopathologyIntervention studiesDepressive symptomatologyPatientsSymptomsOlder personsGeneral psychopathologySuicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life
Kasckow J, Montross L, Golshan S, Mohamed S, Patterson T, Sollanzano E, Zisook S. Suicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life. International Journal Of Geriatric Psychiatry 2007, 22: 1223-1228. PMID: 17506025, PMCID: PMC3118557, DOI: 10.1002/gps.1817.Peer-Reviewed Original ResearchConceptsQuality of lifeMedication Management Ability AssessmentDepressive symptomsQLS scoresUCSD Performance-based Skills AssessmentOlder patientsSocial Skills Performance AssessmentLeast mild degreeDSM-IV criteriaMore depressive symptomsWorse qualityMean ageISS scoreMedication managementMajor depressionMild degreeHeinrichs QualitySchizoaffective disorderPatientsPerformance-Based Skills AssessmentSignificant associationSpearman's rho correlational analysisWorse functioning
2004
Bipolar Disorder in Middle-Aged and Elderly Adults: Is Age of Onset Important?
Depp CA, Jin H, Mohamed S, Kaskow J, Moore DJ, Jeste DV. Bipolar Disorder in Middle-Aged and Elderly Adults: Is Age of Onset Important? The Journal Of Nervous And Mental Disease 2004, 192: 796-799. PMID: 15505527, DOI: 10.1097/01.nmd.0000145055.45944.d6.Peer-Reviewed Original ResearchConceptsLate-onset groupLate-life bipolar disorderAge of onsetBipolar disorderFamily historyLate-onset bipolar disorderAge 40 yearsContinuous variablesCognitive functioningRelationship of ageOlder patientsMedication useClinical featuresCross-sectional designMedication usageMean ageDepressive symptomsOverall psychopathologyDistinct syndromeElderly adultsMeasures of psychopathologyDisordersNeuropsychological functioningAgeNeurobiological aspectsThe Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. DOI: 10.1097/01.jam.0000129822.54487.14.Peer-Reviewed Original ResearchLong-term care settingsOlder patientsAtypical antipsychoticsCare settingsNeurodegenerative disordersSide effectsDouble-blind placebo-controlled trialHigh-potency conventional antipsychoticsLong-term care patientsOpen-label studyPlacebo-controlled trialNewer atypical antipsychoticsOlder patient populationUse of quetiapineUse of risperidoneExtrapyramidal side effectsAtypical antipsychotic medicationsConventional antipsychoticsCare patientsTardive dyskinesiaNovel antipsychoticsAntipsychotic medicationPatient populationPsychopharmacologic agentsAgitation symptomsThe Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. PMID: 15228634, DOI: 10.1016/s1525-8610(04)70130-9.Peer-Reviewed Original ResearchConceptsAtypical antipsychoticsRate of extrapyramidal side effectsHigh-potency conventional antipsychoticsDays of risperidoneAtypical antipsychotic medicationsExtrapyramidal side effectsDay of olanzapineDouble-blind placebo-controlled trialConventional antipsychoticsNovel antipsychoticsAntipsychotic medicationTardive dyskinesiaTreating older patientsPsychopharmacological agentsAgitation symptomsNeurodegenerative disordersAntipsychoticsBehavioral agitationPlacebo-controlled trialOpen-label studyOlder patientsHigh-potencyAripiprazoleOlanzapineRisperidone
2001
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients
Kasckow J, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste D. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. International Journal Of Geriatric Psychiatry 2001, 16: 1163-1167. PMID: 11748776, DOI: 10.1002/gps.508.Peer-Reviewed Original ResearchConceptsCitalopram augmentationScale scoreClinical Global Impression Scale scoresHamilton Depression Rating Scale scoresLarge double-blind studyDepression Rating Scale scoresAugmentation of antipsychoticsUsefulness of antidepressantsDouble-blind studySingle-blind trialMajor side effectsOlder schizophrenia patientsRating Scale scoresStable dosesElderly patientsOlder patientsAntipsychotic treatmentCitalopram groupDepressive symptomsSide effectsPatientsSchizophrenia patientsControl groupNegative symptomsAntipsychotics